CA - Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
2024-04-18 11:26:22 ET
Summary
- Aurinia Pharmaceuticals has the potential for up to 80-100% upside by the end of 2024.
- The company's focus on cost savings and a single product commercial biotech strategy is positive.
- The potential increase in US sales and from international markets paired with cost savings could make Aurinia cash flow positive by the end of the year.
- Future patent challenge to Lupkynis is likely, but defendable.
Editor's note: Seeking Alpha is proud to welcome Pivotal Biotech as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more »